2BO Stock Chart & Stats
€1.65
€0.10(2.35%)
At close: 4:00 PM EST
€1.65
€0.10(2.35%)
Day’s Range― - ―
52-Week Range€1.07 - €6.40
Previous CloseN/A
Volume45.00
Average Volume (3M)14.00
Market Cap
€27.34M
Enterprise Value€93.00K
Total Cash (Recent Filing)€24.53M
Total Debt (Recent Filing)€3.17M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Aug 07, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding14,997,505
10 Day Avg. Volume0
30 Day Avg. Volume14
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-526.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.34Price Target Upside405.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetVery low reported debt (~$0.16M) versus equity (~$17.6M) and a solid asset base (~$27.3M) reduces interest burden and preserves financial flexibility. This durable capital structure supports continued R&D and partnership optionality without near-term leverage constraints.
Platform-based Business Model With Multi-disease ApplicabilityThe proprietary polymer drug-delivery platform is reusable across candidates and disease indications, enabling licensing, co-development, and repeatable program starts. A platform model can diversify technical risk and create durable partnership or revenue streams as programs advance.
Structural Financing Flexibility Via Shareholder ApprovalsThe authorized-share increase and related governance approvals materially expand the company's ability to raise equity, grant incentives, or execute strategic transactions. This structural capacity supports long-term funding of R&D and potential M&A without transactional delays.
Bears Say
Sustained Negative Operating Cash Flow / High Cash BurnTTM operating and free cash flow of roughly -$18.2M represent sustained cash burn that erodes runway absent external financing. Over the next 2–6 months this compels capital raises or spending reductions, limiting strategic freedom and increasing financing and dilution risk.
Minimal Revenue And Large Net LossesWith negligible revenue (~$0.13M TTM) and sizeable net losses (~$21.3M TTM), the business lacks operating leverage and cannot self-fund development. This persistent unprofitability extends reliance on external capital and delays path to sustainable cash generation.
Meaningful Dilution Risk From Large Authorized Share IncreaseAuthorizing up to 125M common shares and expanding incentive plans increases capacity for equity issuance. While it enables funding, this structural change raises long-term dilution risk and can materially affect per-share economics if capital needs are met primarily through equity.
Serina Therapeutics News
2BO FAQ
What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was €1.07 and its highest was €6.40 in the past 12 months.
What is Serina Therapeutics’s market cap?
Serina Therapeutics’s market cap is €27.34M.
When is Serina Therapeutics’s upcoming earnings report date?
Serina Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 21 days.
How were Serina Therapeutics’s earnings last quarter?
Serina Therapeutics released its earnings results on May 14, 2026. The company reported -€0.509 earnings per share for the quarter, missing the consensus estimate of -€0.386 by -€0.123.
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Undervalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate is -0.41.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 14,997,505 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Serina Therapeutics reported an EPS of -€0.509 in its last earnings report, missing expectations of -€0.386. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Serina Therapeutics?
Currently, no hedge funds are holding shares in DE:2BO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Serina Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€8.34 (405.50% Upside)
€8.34 (405.50% Upside)
Insider Transactions
Bought Shares
Worth €9.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.04%
12-Months-Change
Fundamentals
Return on Equity
-402.16%
Trailing 12-Months
Asset Growth
305.57%
Trailing 12-Months
Company Description
Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
2BO Stock 12 Month Forecast
Average Price Target
€8.34
▲(405.50% Upside)
Technical Analysis
Outlook Therapeutics
―
Skye Bioscience
―
Celularity
―
Barinthus Biotherapeutics
―
Jupiter Neurosciences, Inc.
―